Patients with diffuse PC and treated with peptide receptor radionuclide therapy (PRRT) showed peritoneal progression in 37.5% of cases, and bowel obstruction or ascites in 28.1% A better peritoneal disease control was observed in cases receiving somatostatin analogs at first line, probably due to a less aggressive disease behaviour for these patients.